

DeLong Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9337145/publications.pdf>

Version: 2024-02-01

129
papers

6,577
citations

66250

44
h-index

73587

79
g-index

131
all docs

131
docs citations

131
times ranked

11272
citing authors

#	ARTICLE	IF	CITATIONS
1	Palliative care pilot initiative for transplant patients: The Westchester Medical Center experience.. Journal of Clinical Oncology, 2022, 40, e19050-e19050.	0.8	0
2	Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomarker Research, 2021, 9, 15.	2.8	42
3	Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. Journal of Hematology and Oncology, 2021, 14, 66.	6.9	35
4	Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, JCO.20.01739.	0.8	10
5	Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomarker Research, 2021, 9, 62.	2.8	18
6	The Safety and Efficacy of Granulocyte Transfusions in Pediatric Recipients with Severe Neutropenia. Blood, 2021, 138, 2148-2148.	0.6	3
7	Patterns of Family History of Cancer in Adults with Hematologic Malignancies. Blood, 2021, 138, 4378-4378.	0.6	0
8	BCMA-targeted immunotherapy for multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 125.	6.9	108
9	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29.	6.9	146
10	Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases. Blood, 2020, 136, 32-33.	0.6	0
11	Frontline therapies for untreated chronic lymphoid leukemia. Experimental Hematology and Oncology, 2019, 8, 15.	2.0	11
12	Engineering switchable and programmable universal CARs for CAR T therapy. Journal of Hematology and Oncology, 2019, 12, 69.	6.9	65
13	Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomarker Research, 2019, 7, 24.	2.8	39
14	CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. Journal of Hematology and Oncology, 2019, 12, 113.	6.9	69
15	Recent advances on blinatumomab for acute lymphoblastic leukemia. Experimental Hematology and Oncology, 2019, 8, 28.	2.0	31
16	Recent updates on CAR T clinical trials for multiple myeloma. Molecular Cancer, 2019, 18, 154.	7.9	71
17	Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. Journal of Hematology and Oncology, 2019, 12, 94.	6.9	70
18	Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research, 2019, 7, 19.	2.8	44

#	ARTICLE	IF	CITATIONS
19	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomarker Research, 2019, 7, 9.	2.8	19
20	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. Journal of Hematology and Oncology, 2019, 12, 17.	6.9	80
21	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2019, 12, 15.	6.9	38
22	Cancer biomarkers for targeted therapy. Biomarker Research, 2019, 7, 25.	2.8	72
23	Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. Journal of Hematology and Oncology, 2018, 11, 138.	6.9	17
24	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. Journal of Hematology and Oncology, 2018, 11, 142.	6.9	95
25	Universal CARs, universal T cells, and universal CAR T cells. Journal of Hematology and Oncology, 2018, 11, 132.	6.9	184
26	Cytokine release syndrome: grading, modeling, and new therapy. Journal of Hematology and Oncology, 2018, 11, 121.	6.9	99
27	SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms. Biomarker Research, 2018, 6, 29.	2.8	13
28	Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report. Frontiers of Medicine, 2018, 12, 593-599.	1.5	6
29	CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. Journal of Hematology and Oncology, 2018, 11, 41.	6.9	44
30	Development and Evaluation of CART Targeting Bcma with Humanized Alpaca-Derived Single-Domain Antibody As Antigen Recognition Domain. Blood, 2018, 132, 1976-1976.	0.6	7
31	A nationwide analysis of palliative care service utilization in hospitalized metastatic cancer patients.. Journal of Clinical Oncology, 2018, 36, 6602-6602.	0.8	2
32	Successful Treatment with Intrathecal Tocilizumab(IL-6 antibody) for 2 Cases of Graft-Versus Host Disease of the Central Nervous System after a Second Allogeneic HSCT from Haploidentical Donor. Blood, 2018, 132, 5730-5730.	0.6	1
33	Compound Application of Thalidomide and Recombinant Human Interferon- γ -1b, Interleukin-2 in Different Disease Status of Acute Myeloid Leukemia a Multi-Center Prospective Study of a New Combination of Old Drugs. Blood, 2018, 132, 5219-5219.	0.6	0
34	Treatment of Epstein-Barr Virus Associated Central Nervous System Diseases after Allogeneic Hematopoietic Stem Cell Transplantation with Intrathecal Donor Lymphocyte Infusion. Blood, 2018, 132, 5685-5685.	0.6	0
35	Evaluation of Romylocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy. Blood, 2018, 132, 1407-1407.	0.6	1
36	Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Experimental Hematology and Oncology, 2017, 6, 4.	2.0	18

#	ARTICLE	IF	CITATIONS
37	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. <i>Journal of Hematology and Oncology</i> , 2017, 10, 34.	6.9	82
38	Diagnosis and treatment of CD20 negative B cell lymphomas. <i>Biomarker Research</i> , 2017, 5, 5.	2.8	20
39	Clinical applications of PD-L1 bioassays for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 110.	6.9	66
40	Clinical trials of CAR-T cells in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 166.	6.9	62
41	Increased Mortality Among Patients With Acute Leukemia Admitted on Weekends Compared to Weekdays. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e33-e43.	0.2	5
42	EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. <i>Cancer Letters</i> , 2017, 385, 51-54.	3.2	215
43	Syk inhibitors in clinical development for hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 145.	6.9	130
44	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	6.9	92
45	SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome. <i>Biomarker Research</i> , 2017, 5, 33.	2.8	12
46	Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. <i>Oncotarget</i> , 2017, 8, 7201-7207.	0.8	27
47	Differences in mortality among patients with acute leukemia admitted on weekends as compared to weekdays.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6576-6576.	0.8	0
48	A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient. <i>Stem Cell Investigation</i> , 2016, 3, 25-25.	1.3	3
49	Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support. <i>Stem Cell Investigation</i> , 2016, 3, 27-27.	1.3	18
50	CD34+ therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer. <i>Stem Cell Investigation</i> , 2016, 3, 7-7.	1.3	3
51	Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report. <i>Stem Cell Investigation</i> , 2016, 3, 8-8.	1.3	4
52	Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells. <i>Journal of Hematology and Oncology</i> , 2016, 9, 3.	6.9	15
53	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 34.	6.9	231
54	Second-generation inhibitors of Bruton tyrosine kinase. <i>Journal of Hematology and Oncology</i> , 2016, 9, 80.	6.9	173

#	ARTICLE	IF	CITATIONS
55	EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 59.	6.9	143
56	Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. <i>Frontiers of Medicine</i> , 2016, 10, 383-388.	1.5	76
57	CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients. <i>Leukemia Research</i> , 2016, 46, 74-78.	0.4	5
58	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. <i>Journal of Hematology and Oncology</i> , 2016, 9, 21.	6.9	181
59	Second- and third-generation ALK inhibitors for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 19.	6.9	116
60	Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells. <i>Oncotarget</i> , 2016, 7, 26567-26579.	0.8	6
61	Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. <i>Experimental Hematology and Oncology</i> , 2015, 5, 20.	2.0	8
62	Cell therapy must be regulated as medicine. <i>Experimental Hematology and Oncology</i> , 2015, 5, 26.	2.0	3
63	Distinct genetic alterations in small cell carcinoma from different anatomic sites. <i>Experimental Hematology and Oncology</i> , 2015, 4, 2.	2.0	30
64	ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. <i>Journal of Hematology and Oncology</i> , 2015, 8, 129.	6.9	223
65	Novel ALK inhibitors in clinical use and development. <i>Journal of Hematology and Oncology</i> , 2015, 8, 17.	6.9	81
66	Pass quantity, focus on quality. <i>Journal of Hematology and Oncology</i> , 2015, 8, 27.	6.9	1
67	Selective inhibitors of nuclear export (SINE) in hematological malignancies. <i>Experimental Hematology and Oncology</i> , 2015, 4, 7.	2.0	52
68	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 96.	6.9	84
69	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 104.	6.9	139
70	CLAG-Based Induction Therapy in Previously Untreated High Risk AML Patients. <i>Blood</i> , 2015, 126, 4892-4892.	0.6	1
71	Novel agents for advanced pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 39521-39537.	0.8	29
72	Franklin's disease: immunoglobulin heavy chain disease. <i>Stem Cell Investigation</i> , 2015, 2, 1.	1.3	0

#	ARTICLE	IF	CITATIONS
73	Selective inhibitors of nuclear export (SINE)â€™ a novel class of anti-cancer agents. Journal of Hematology and Oncology, 2014, 7, 78.	6.9	111
74	Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells. Experimental Hematology and Oncology, 2014, 3, 5.	2.0	41
75	Ibrutinib for B cell malignancies. Experimental Hematology and Oncology, 2014, 3, 4.	2.0	68
76	CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomarker Research, 2014, 2, 12.	2.8	4
77	Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. Frontiers of Medicine, 2014, 8, 254-258.	1.5	0
78	Isolated factor V deficiency in a patient with elevated PT and aPTT during routine pre-operative laboratory screening. Stem Cell Investigation, 2014, 1, 4.	1.3	3
79	Megakaryocytes regulate the quiescence of hematopoietic stem cells through PF4: 2013 ASH meeting highlights. Stem Cell Investigation, 2014, 1, 8.	1.3	0
80	Multiple myeloma with leptomeningeal involvement and positive CSF. Stem Cell Investigation, 2014, 1, 21.	1.3	1
81	Chimeric antigen receptor (CAR)-directed adoptive immunotherapy: a new era in targeted cancer therapy. Stem Cell Investigation, 2014, 1, 2.	1.3	9
82	B-Raf and the inhibitors: from bench to bedside. Journal of Hematology and Oncology, 2013, 6, 30.	6.9	80
83	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Journal of Hematology and Oncology, 2013, 6, 88.	6.9	211
84	Ibrutinib and novel BTK inhibitors in clinical development. Journal of Hematology and Oncology, 2013, 6, 59.	6.9	194
85	STAT inhibitors for cancer therapy. Journal of Hematology and Oncology, 2013, 6, 90.	6.9	157
86	Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomarker Research, 2013, 1, 1.	2.8	57
87	Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Research, 2013, 1, 5.	2.8	146
88	MEK and the inhibitors: from bench to bedside. Journal of Hematology and Oncology, 2013, 6, 27.	6.9	219
89	High-dose cytarabine-mitoxantrone versus hyper-CVAD in adult acute lymphoblastic leukemia and Burkittâ€™s lymphoma: A single center experience of two induction regimens.. Journal of Clinical Oncology, 2013, 31, 7076-7076.	0.8	0
90	Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell International, 2012, 12, 38.	1.8	8

#	ARTICLE	IF	CITATIONS
91	Recent advances and novel agents for gastrointestinal stromal tumor (GIST). Journal of Hematology and Oncology, 2012, 5, 21.	6.9	30
92	Novel CD20 monoclonal antibodies for lymphoma therapy. Journal of Hematology and Oncology, 2012, 5, 64.	6.9	116
93	CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology and Oncology, 2012, 1, 36.	2.0	398
94	Current management and prognostic features for gastrointestinal stromal tumor (GIST). Experimental Hematology and Oncology, 2012, 1, 14.	2.0	52
95	Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Experimental Hematology and Oncology, 2012, 1, 10.	2.0	227
96	Current management and novel agents for malignant melanoma. Journal of Hematology and Oncology, 2012, 5, 3.	6.9	39
97	A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. Journal of Hematology and Oncology, 2011, 4, 46.	6.9	72
98	High Response Rate and Prolonged Survival in Patients with Primary Refractory Acute Myelogenous Leukemia Treated with Decitabine Salvage Therapy. Blood, 2011, 118, 4280-4280.	0.6	1
99	A Meta-Analysis of CAG (cytarabine, aclarubicin, G-CSF) Regimen for the Treatment of 1045 Patients with Leukemia in China and Japan,. Blood, 2011, 118, 3638-3638.	0.6	0
100	CAG (cytarabine, aclarubicin, G-CSF) Regimen Is Effective and Well Tolerated in 367 Elderly Patients with AML in China and Japan: A Meta-Analysis. Blood, 2011, 118, 4290-4290.	0.6	0
101	Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology and Oncology, 2010, 3, 5.	6.9	373
102	Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. Journal of Hematology and Oncology, 2010, 3, 17.	6.9	52
103	Meta-Analysis of CAG (cytarabine, aclarubicin, G-CSF) Regimen for the Treatment of 580 Patients with Acute Leukemia In China and Japan.. Blood, 2010, 116, 1064-1064.	0.6	1
104	Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.. Blood, 2009, 114, 1770-1770.	0.6	7
105	The Research of Phenylhexyl Isothiocyanate's Influence on p16 Gene Methylation of Leukaemia Cell. Blood, 2008, 112, 4497-4497.	0.6	0
106	Rasburicase Effectively Lowers Serum Uric Acid Levels in High Risk, Poor Performance Status Patients with Hematologic Malignancies. Blood, 2008, 112, 4012-4012.	0.6	0
107	Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CPCML).. Blood, 2008, 112, 2128-2128.	0.6	0
108	t(8;14;18): A 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia. Molecular Cancer, 2007, 6, 35.	7.9	23

#	ARTICLE	IF	CITATIONS
109	Haplo-Identical Allogeneic Stem Cell Transplantation Using G-CSF-Mobilized Marrow Plus Blood Stem Cells from Parent Donors for Children with High-Risk Leukemia.. Blood, 2007, 110, 5084-5084.	0.6	0
110	Pegylated Recombinant Human Arginase, Rharg-Peg5,000MW, Targets Cell Cycle Machinery in Multiple Myeloma Cells.. Blood, 2007, 110, 4095-4095.	0.6	0
111	The Epigenetic Effect of Phenylhexyl Isothiocyanate on Histone Acetylation in Patients with Acute Leukemia and Non-Leukemic Disorders.. Blood, 2007, 110, 4145-4145.	0.6	0
112	Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.. Blood, 2007, 110, 4383-4383.	0.6	0
113	A Novel Method of Microarray Quantitative Analysis of P16 CPG Island Methylation in Leukemia Cells from Patients with Hematological Malignancies.. Blood, 2007, 110, 4140-4140.	0.6	0
114	A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.. Blood, 2006, 108, 168-168.	0.6	30
115	Phase I Study of Temozolomide and Cisplatin in Patients with Acute Leukemia.. Blood, 2006, 108, 4542-4542.	0.6	1
116	Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.. Blood, 2006, 108, 4546-4546.	0.6	0
117	Phenylhexyl Isothiocyanate, a Novel Inhibitor of Histone Deacetylation and Methylation, Induce Growth Arrest and Apoptosis of Myeloma Cells.. Blood, 2006, 108, 5033-5033.	0.6	0
118	Phenylhexyl Isothiocyanate, a Dual Inhibitor of Histone Deacetylation and Methylation, Inhibit Acute Lymphoblastic Leukemia Cells through Epigenetic Modulation.. Blood, 2006, 108, 4532-4532.	0.6	0
119	Assessing DNA Damage Ex Vivo Induced by Chemotherapy Targeting Topoisomerase Inhibitors in Acute Leukemias.. Blood, 2006, 108, 4372-4372.	0.6	0
120	PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma. Leukemia Research, 2005, 29, 591-594.	0.4	14
121	Phenylhexyl Isothiocyanate, a New Histone Deacetylase Inhibitor, Can Prevent Tumor Formation and Inhibit Leukemia Cell Growth In Vivo.. Blood, 2005, 106, 4625-4625.	0.6	0
122	Nonmyeloablative Allogeneic Stem Cell Transplantation for a Case of Refractory Systemic Lupus Erythematosus.. Blood, 2005, 106, 5411-5411.	0.6	0
123	High-Dose Mitoxantrone-Based Induction Therapy in Newly-Diagnosed AML. Results of 171 Patients Treated at NYMC between 1991-2003.. Blood, 2005, 106, 1859-1859.	0.6	0
124	A Novel Method of Isolation of Mesenchymal Stem Cells from Human Umbilical Cord Tissues.. Blood, 2005, 106, 4306-4306.	0.6	0
125	Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leukemia Research, 2004, 28, 61-63.	0.4	33
126	An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomes in Cancer Patients with Chemotherapy-Induced Anemia.. Blood, 2004, 104, 5310-5310.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Progressively Intensified Chemotherapy: A Phase II Trial in Patients with Multiple Myeloma.. Blood, 2004, 104, 4951-4951.	0.6	0
128	Col-6, a Compound Found in Edible Plants, Induces Apoptosis of Human Leukemia Cells and Down-Regulate Bcl-2 Expression.. Blood, 2004, 104, 4380-4380.	0.6	0
129	Phase II Study of Gemtuzumab Ozogamycin (GO) and Cytarabine (ARA-C) in Patients with High Risk MDS and AML... Blood, 2004, 104, 4723-4723.	0.6	0